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Abstract
Background: Recent investigations suggest a possible common genetic background between Autism Spectrum
Disorders (ASD) and Celiac Disease (CD). However, studies regarding this association are scarce and often limited by
the small sample sizes and/or large heterogeneity among ASD groups in terms of demographic and clinical
features. The present study aims to investigate the overall CD prevalence (biopsy proven-CD patients plus screening
detected tTG and EMA positive cases) in a large population of pre-schoolers with ASD referred to a tertiary care
University Hospital.
Methods: We retrospectively collected data about 382 children (mean age: 46.97 ± 13.55 months; age-range: 18-72
months) consecutively diagnosed as ASD (according to the Diagnostic and Statistical Manual of Mental Disorders
4th edition criteria) over the period 2010–2013, and who performed a serological CD screening.
Results: The overall CD prevalence was 2.62%, which is statistically significant higher to that reported in the Italian
paediatric population (p = 0.0246). Half of these children had no symptoms or risk factors related to CD when they
performed the serological screening.
Conclusions: If replicated, these data suggest the importance of regular screening for CD in young patients with
ASD, and are of relevance for clinical and public health.
Keywords: Celiac Disease, Autism Spectrum Disorders, Pre-schoolers, Screening, Autoimmune disease,
Gastrointestinal symptoms, Epidemiology, Young children
Background
Autism Spectrum Disorders (ASD) are neurodevelop-
mental conditions characterized by impairment in
socio-communicative abilities as well as restricted and
stereotyped behaviours [1]. Besides the aforementioned
core symptoms, patients with ASD frequently show a
wide range of associated clinical manifestations, includ-
ing other psychiatric [2], and medical comorbidities [3].
Among these latter, gastrointestinal (GI) dysfunctions
are reported by parents of ASD children with a rate of
20–85% depending both on definition of GI symptoms
and demographic/clinical characteristics of ASD samples
[4, 5]. Simultaneously, recent evidences suggest a role of
immune dysfunction in ASD pathogenesis [6], sustained
also by increased rates of autoimmune disorders in the
families of subjects with ASD [7–9]. In this framework,
a possible association between ASD and Celiac Disease
(CD) has been suggested. CD is defined as “a chronic
small intestinal immune-mediated enteropathy pre-
cipitated by exposure to dietary gluten in genetically
predisposed individuals” [10]. The prevalence of CD in
Western population is close to 1% [11]; in particular in
Italy it was estimated to be 1.1% among children aged
0–16 years [12], and 1.2% among school children, on the
basis of a salivary radio-immunological screening [13].
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Clinical manifestations in childhood are not limited to
classical GI symptoms (diarrhoea, abdominal pain, bloat-
ing, flatulence, weight loss, anorexia, constipation), but in-
clude other common or atypical manifestations potentially
affecting any organ or body system. Moreover, two asymp-
tomatic forms are described: Silent CD characterized by
positive serology and histology, and Potential CD with
positive serology and compatible Human Leukocyte Anti-
gen (HLA) alleles but negative histology [14, 15]. Several
complications are associated with untreated CD, and an
increased risk of overall mortality has been observed [16].
The association between ASD and CD is still a matter of
debate. Some studies reported no evidence for the exist-
ence of a ASD-CD link [17–19], whereas others suggested
a possible connection [20], or a higher prevalence of CD
in ASD children than in general pediatric population [21].
Ludvigsson and colleagues [22] found that ASD was asso-
ciated with an increased risk of positive CD serology. It is
worth noting that, according to one of the “gut-to-brain-
connection” theories in ASD, gluten (and casein) can trig-
ger inflammation in the gut leading to autoimmune illness
or cross-reactivity with other potential central nervous
system antigens [23, 24]. Therefore, the supposed relation-
ship between gluten and ASD has paved the way for indis-
criminate therapeutic approaches such as gluten (and/or
casein) free diet, bereft of scientifically validated benefits
in absence of a CD diagnosis, as assessed by two recent
reviews [25, 26]. A further reason for the scientific com-
munity to better clarify the possible links of ASD and CD.
The aim of this study was to detect the prevalence of
CD in a large series of carefully diagnosed ASD preschool
children referred to a tertiary care University Hospital.
Methods
Participants
We retrospectively reviewed data of inpatient and
day-patient preschool children who had received a
first clinical evaluation with a diagnosis of Autistic
Disorder, Asperger’s Disorder or Pervasive Develop-
mental Disorder-Not Otherwise Specified according to
the DSM-IV-TR criteria [27] at the IRCCS Stella
Maris Foundation (Pisa, Italy) between January 2010
and December 2013. The sample was composed of
382 children, 304 males and 78 females with an average
age of 46.97 months (standard deviation: 13.55 months;
range: 18–72 months). ASD diagnosis was performed by a
multidisciplinary team (a senior child psychiatrist, an ex-
perienced clinically trained research child psychologist, an
educational therapist, and a speech-language pathologist)
during 5–7 days of extensive evaluation, and confirmed by
the Autism Diagnostic Observation Schedule-Generic
(ADOS-G) [28] in the large majority of subjects. Exclusion
criteria were: (a) neurological syndromes or focal
neurological signs; (b) significant sensory impairment
(e.g., blindness, deafness); (c) potential secondary causes
of ASD revealed by high-resolution karyotyping, DNA
analysis of Fragile-X, or screening tests for inborn errors
of metabolism.
Celiac disease screening and diagnosis
During the first evaluation in the ASD Operative Unit of
our Institute, all children usually undergo a serological
screening for CD as part of the routine assessment through
the determination of the titres of Anti-Gliadin (AGA)
immunoglobuline (Ig)A and IgG, Anti-Transglutaminase
(anti-tTG) IgA, and Anti-Endomysium (EMA) IgA anti-
bodies. The first two antibodies are quantified, respectively,
with fully automated EliA™ Gliadin and EliA™ Celikey® on
ImmunoCAP 250 (Phadia), and measured with fluorescent
enzyme immunoassay (FEIA). The upper limit of their
physiological range is 10 U/ml values; between 7 and 10 U/
ml are considered “borderline”; values under 7 U/ml are
considered negative. EMA IgA is measured with indirect
immunofluorescence on Euroimmun slides, and it is
subject to significant variability of interpretation, but its
specificity is very high (98–100%) [15]. Possible EMA re-
sults in our sample were: “+”: positive result; “-”: negative
result; “+/-”: doubt/borderline result. We retrieved the
results of the CD screenings from the digital database of
the Clinical Pathology Laboratory of St Chiara Hospital
(Pisa, Italy). According to the European Society for
Pediatric Gastroenterology, Hepatology, and Nutrition
(ESPGHAN) new guidelines for the CD diagnosis [15, 29],
the serological diagnosis of CD is based on the detection of
class IgA anti-tTG and EMA antibodies; in patients with
IgA deficiency, IgG anti tTG is used. Specifically, the sensi-
tivities for both tTG and EMA antibodies ranged from 70
to 100% [30]. In a large, prospective, biopsy-confirmed
study on adult patients without a previous known diagno-
sis of CD, the negative predictive value for IgA tTG was
99.6%, and it increased to 99.7% when a two-step approach
was adopted, using tTG first and EMA then [31]. The spe-
cificity for tTG ranged from 91 to 100%, whereas EMA
specificity is even higher (98–100%), so much that this test
is considered specific for a diagnosis of CD [30]. A positiv-
ity of both anti-tTG and EMA antibodies has a sensitivity
and positive predictive value for CD close to 100% [30, 32].
A confirmation of the CD diagnosis is recommended to all
individuals positive for anti-tTG and/or EMA antibodies.
Therefore, we selected from the sample all subjects with
positive or borderline values of anti-tTG and/or EMA
antibodies at the serological screening and then checked in
the patient’s medical records or through call interviews
whether the CD diagnosis had been subsequently con-
firmed by paediatric gastroenterologists. We did not took
into account the screening levels of AGA IgA and IgG
antibodies for the purposes of this study since they have
been recently considered as the less specific markers of
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inflammation due to dietary gluten, their increase may be
explained by an array of diseases and its significance is still
under debate [15, 29].
Since we aimed to compare the overall prevalence of CD
in our sample to that found in the general population, we
used the data from the survey of Mustalahti et al. [12],
which investigated the CD prevalence in four European
countries -Italy included- by analyzing the sera from 29,212
children and adults. The Italian sample of children was
composed of 2649 individuals with an age-range from 0 to
19 years (the means and standard deviations values were
not reported). The age range of our sample was quite differ-
ent from that of this European survey [12] (1.5–6 years
versus 0–19 years). Therefore, since the prevalence of CD
tends to increase by age [33], an underestimation of CD
prevalence in our ASD population could not be excluded
when it is compared to the prevalence of the Italian
children included in the European survey, i.e. 1.1% (95% CI:
0.7–1.5), derived from “previously diagnosed biopsy-proven
CD patients plus screening detected individuals with both
anti-tTG and EMA positivity” [12].
Statistical analysis
Statistical calculations were performed with SPSS® version
19.0. We performed the Chi-square test to compare the
prevalence of CD between our sample and the Italian
pediatric population [12]. A p-value <0.05 was considered
significant.
Results
Among 382 pre-schoolers with ASD, the retrospective re-
view of their medical records identified ten patients with
CD or with positive CD serology (Table 1). In particular,
nine subjects resulted serologically positive for anti-tTG
IgA and/or EMA antibodies during their first neuropsychi-
atric evaluation. In seven of these children (patients 1–7),
the diagnosis of CD was confirmed by paediatric gastroen-
terologists: (a) through multiple duodenal biopsies (subjects
1–5); (b) on the basis of very high anti-tTG antibody levels
and HLA positivity (patient 6); (c) on the presence of
Duhring-Brocq dermatitis herpetiformis, a chronic bullous
disease specifically correlated with sensitivity to gluten en-
teropathy and CD (patient 7) [34]. All these patients were
on a gluten-free diet (GFD). As far as patient 8 is con-
cerned, we were not able to obtain any further information
since his parents were no more contactable after the sero-
logical screening. The patient 9 did not perform further
evaluations even in the presence of repeated positivity of
CD serology due to parents’ refusal. The patient 10 was
already diagnosed as celiac and was on a GFD at the time
of the first clinical evaluation in our hospital. She had per-
formed CD serological screening at the age of 32 months
since she showed growth failure and dental enamel defects.
She resulted serologically positive for anti-tTG IgA and
EMA antibodies, and eventually CD diagnosis was con-
firmed by multiple duodenal biopsies and HLA positivity.
All in all, patients with CD or with positive CD ser-
ology were ten, six males and four females, with mean
age of 41 months (SD: 15.2; range: 20–67). Therefore,
the prevalence of “CD patients plus screening detected
individuals with both anti-tTG and EMA positivity” was
2.62% (10/382 subjects).
The Chi square test (see Table 2) indicated a statistically
significant difference (p value = 0.0131) in the prevalence
of CD cases identified in our sample (2.62%; 95% CI:
1.0–4.2) as compared to the sample obtained from the
Italian paediatric population (1.1%; 95% CI: 0.7–1.5) [12].
Of the ten subjects with CD (or positive CD serology),
four patients (40%: the patients No 1, 5, 7, and 10)
showed one or more symptoms suggestive of a typical
form of CD. Patient No 3 was asymptomatic, but
belonged to a high risk group given a positive familiarity
Table 1 Serology, clinical data and diagnosis confirmation of the ten ASD subjects with CD or positive CD serology
No. Age (months) Sex tTG Ig A (U/ml) EMA AGA IgA (U/ml) AGA IgG (U/ml) Risk factor and clinical presentation CD diagnosis
1 27 F >200.0 + 15.0 127.0 Inappetence MDB +
2 67 M 40.7 + 8.0 18.9 None MDB +
3 41 M 35.0 + 9.3 41.0 CD in the sister MDB +
4 44 M 102.0 + 1.4 1.1 None MDB +
5 24 F 11.6 - 0.2 6.4 Diarrhea MDB +
6 60 M >200 + 93.0 85.5 None HLA +
7 44 F 3.6 +/- 1.2 17.0 Growth failure DH
8 20 M 23.0 + 1.4 9.0 None n.p.
9 44 M 15.0 + 1.6 9.6 None n.p.
10a 58 F n.a. n.a. n.a. n.a. Growth failure Dental enamel defects MDB +, HLA +
M male, F female, tTG Ig A anti-transglutaminase antibodies, EMA anti-endomysium antibodies, AGA IgA and IgG: anti-gliadin antibodies; cut -off values for tTG IgA,
AGA IgA and AGA IgG: positive: > 10U/ml; borderline: 7–10 U/ml, negative: <7 U/ml; EMA: “+”: positive result; “-“: negative result; “+/-“: doubt result; n.p. not
performed, n.a. not available, HLA+ human leukocyte antigen positivity, MDB +multiple duodenal biopsies positivitym, DH Duhring Dermatitis Herpetiformis
aASD patient who had received a CD diagnosis before the hospitalization in our ASD Unit and for which serological data are not available
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for CD. Five patients (50%) had no symptoms or risk
factors correlated with CD at the time of the serological
screening.
Discussion
Our results indicate that an association between ASD and
CD cannot be excluded. The comparison of our findings
with those of previous studies is complex given several
differences in the study design (prevalence of ASD in CD
children or viceversa), in CD serological screening method-
ologies (only tTG, both EMA and tTG, AGA and/or EMA
and/or tTG antibodies positivity), and in the ASD samples
(in terms of size, age of patients, severity of ASD symptoms,
diagnostic evaluation and diagnostic criteria). The first
studies were performed in the 70’ies [35, 36] and they both
did not find any significant association between autism and
CD. Some more recent studies also rejected the ASD-CD
link. In particular, Batista et al. [17] found no significant
differences in the prevalence of CD in 147 ASD patients
compared to a group of 2034 children and adolescents
originating from the same geographical region and from a
similar low-income stratum. In the same work, the preva-
lence of ASD in 211 patients with CD was 0.95% and there-
fore not significantly different from the prevalence of 0.9%
found in the general US population. Pavone et al. [18], in a
case-control study, found no cases of autism in 120 patients
with CD, and no cases of CD in 11 patients with autism.
On the contrary, Barcia et al. [21] studied retrospectively a
large population of 150 randomly selected patients with
ASD, and found an increased prevalence of intestinal
biopsy-confirmed CD in ASD children (3.3%) compared to
the normal population (0.9%). This prevalence (3.3%) is
quite similar to that found in our work (2.62%). It is to note
that, while Barcia and colleagues included only biopsy-
confirmed CD patients, we considered as CD patients also
the two children without a histological confirmation of the
diagnosis, but with both tTG and EMA positive antibodies.
We made this choice in agreement with some authors [12]
who recently argued that “even if the small intestinal biopsy
has an indisputable diagnostic role in the clinical setting,
this invasive investigation is not an essential requirement
for an epidemiological survey”. Besides, in several epi-
demiological studies the antibody positivity has been
considered as the only criterion for CD diagnosis [37–39].
In another recent work, Ludvigsson et al. [22] collected
data on 26,995 individuals with CD, 12,304 individuals with
inflammation, and 3719 individuals with normal mucosa
but positive CD serology (AGA IgA/IgG, EMA and tTG),
and compared them with 213,208 age- and sex-matched
controls. They found that having a prior diagnosis of ASD
was not associated with CD (OR= 0.93) or inflammation
(OR = 1.03), but was related with a markedly increased risk
of positive CD serology (OR = 4.57) [22]. Our findings dif-
fered from Ludviggson and colleagues [22] as for the pos-
sible association of ASD and CD but it is to note that they
estimated the prevalence of ASD diagnosis in subjects that
had just performed an intestinal biopsy, while we examined
the prevalence of CD diagnosis after a serological screening
in a cohort of subjects diagnosed as ASD. Moreover, the
definition of positive CD serology also differed between
Ludviggson et al. [22] and the current investigation since
they included subjects with positive AGA IgG and IgA anti-
bodies, while we did not take into account the values of
these antibodies. In fact, the main purpose of the present
study was to define the prevalence of CD, and AGA
antibodies are now considered as the less specific markers
of CD in the serological screenings [15].
Among the GI symptoms reported by parents of
children with ASD and CD in our sample there were
diarrhea and inappetence. The former is one of the most
frequently reported GI symptoms in ASD children in
several studies [5, 40] while the latter has been recently
detected as one of the most common GI symptoms in a
large sample of pre-schoolers with ASD [41]. Besides,
half of the ASD children with CD were asymptomatic at
the time of the serological screening: this prevalence
could be ascribed not only to the presence of true
asymptomatic forms of CD but also to the severe com-
munication difficulties of non-verbal preschool children
with ASD, making them unable to express GI and
systemic symptoms suggestive of CD (e.g. recurrent
abdominal pain, abdominal distension, chronic fatigue)
[4, 42]. Otherwise, pre-schoolers with ASD could show
their GI-related distress in alternative ways through a
greater severity of problem behaviors such as irritability
[43], anxiety and affective problems [44, 45], or










Group 1 Our study 10 372 382 0.0131*
Group 2 Mustalahti et al., 2010 [12] 29 2616 2645
Total 39 2988 3027
*The result is significant at p <0.05
1# Children with celiac disease (CD) defined as “previously diagnosed biopsy-proven CD patients plus screening detected individuals with both anti-tTG and
EMA positivity”
2# Children without CD defined as “previously diagnosed biopsy-proven CD patients plus screening detected individuals with both anti-tTG and EMA positivity”
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externalizing behaviors (oppositional defiant behaviors
and tantrums) [46]. These clinical data contributed to
highlight the importance of a serological screening for
CD in young children with ASD, even in absence of
clear GI or systemic symptoms or other risk factors
related to CD.
A possible limitation of the current study was the ab-
sence of data about total IgA level on all ASD patients.
Consequently, a certain number of children with CD
and anti IgA deficiency could be not detected leading to
an underestimation of CD prevalence in our ASD
population. Another possible source of CD prevalence
underestimation in our ASD sample could be ascribed
to the young age of patients included that does not allow
to identify ASD individuals at genetic risk for CD who
develop CD only later. Moreover, we were not able to
provide ADOS-G [28] scores, since this instrument was
originally used for clinical purposes only (in order to
confirm the ASD diagnosis), and therefore his scores
were not usable for research purposes.
Conclusion
Our results indicate that children with ASD may be at
increased risk of CD. This finding has implications be-
yond medical status for children with ASD. Specifically,
the fact that GI symptoms suggestive of CD are difficult
to express in words by non-verbal or minimally-verbal
preschoolers with ASD implies a possible manifestation of
GI-related distress through behavioral symptoms, includ-
ing increased anxiety, decreased social responsiveness,
temper tantrums, opposition, sleep problems, food select-
ivity, aggressive and self-injurious acts [4, 41, 47, 48]. In
these cases, if a diagnosis of CD is confirmed, the
treatment of ASD patients for CD with a gluten-free diet
may not only alleviate their CD-related symptoms, but
also have a positive impact on associated behavioral
problems. Therefore, the screening for CD in young
patients with ASD could be important for decreasing
current and long-term morbidity, as well as increasing
overall health and quality of life.
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